WALTHAM, Mass., May 28, 2019 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will participate in the following conferences in June:
- BIO International Convention 2019 on Monday, June 3, 2019 at 3:00 p.m. ET in Philadelphia, PAPanel Presentation: What’s Next: The Landscape of Innovation in 2019 and Beyond Session ID: 537703
- CNS Targets and Translational Strategies on Wednesday, June 19, 2019 at 8:05 a.m. ET in Boston, MAPresentation: Harnessing the Gut-Brain Axis to Discover Novel CNS Therapeutics
- JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 11:30 a.m. ET in New York, NY
About Axial Therapeutics
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.
Contacts for Axial Therapeutics
Media:
Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com
Investors:
Jeffrey Young, CFO
781-701-8467
jeffrey@axialtx.com